Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Jevtana, Cabazitaxel, Prostatic Neoplasms, Date of Authorisation: 17/03/2011, Revision: 17, Status: Authorised
Case Medical Research
doi 10.31525/cmr-1ecee1f
Full Text
Open PDF
Abstract
Available in
full text
Date
October 9, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Xgeva, Denosumab, Fractures, Bone,Neoplasm Metastasis, Date of Authorisation: 13/07/2011, Revision: 17, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Lenvima, Lenvatinib, Thyroid Neoplasms, Date of Authorisation: 28/05/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Cayston, Aztreonam, Cystic Fibrosis,Respiratory Tract Infections, Date of Authorisation: 21/09/2009, Revision: 17, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Levetiracetam Sun, Levetiracetam, Epilepsy, Date of Authorisation: 14/12/2011, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Mysimba, Naltrexone / Bupropion, Obesity,Overweight, Date of Authorisation: 26/03/2015, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Silodosin Recordati, Silodosin, Prostatic Hyperplasia, Date of Authorisation: 07/01/2019, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Lumigan, Bimatoprost, Glaucoma, Open-Angle,Ocular Hypertension, Date of Authorisation: 08/03/2002, Revision: 30, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Cymbalta, Duloxetine, Anxiety Disorders,Diabetic Neuropathies,Depressive Disorder, Major, Date of Authorisation: 17/12/2004, Revision: 26, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Olanzapine Glenmark Europe, Olanzapine, Schizophrenia,Bipolar Disorder, Date of Authorisation: 03/12/2009, Revision: 10, Status: Authorised
Case Medical Research
